Trial Profile

Open label study to assess efficacy and safety of the fully human anti tumour necrosis factor alpha monoclonal antibody adalimumab

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adalimumab (Primary) ; Methotrexate
Indications Rheumatoid arthritis
Focus Adverse reactions; Therapeutic Use
Acronyms PROWD
Sponsors Abbott Laboratories

Most Recent Events

23 Jun 2016 Results of safety analysis of this and other trials published in the Annals of the Rheumatic Diseases.
13 Jun 2009 Results were reported at the 2009 EULAR.
16 Apr 2008 New trial record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com